Onconova Therapeutics Announces Topline Results from the Pivotal Phase 3 INSPIRE Trial
August 24, 2020 07:30 ET
|
Onconova Therapeutics, Inc.
IV rigosertib did not meet primary endpoint of significantly improved survival versus best supportive care in higher-risk myelodysplastic syndromes (HR-MDS) Onconova will focus on promising...
Onconova Therapeutics Highlights Corporate Progress and Reports Second Quarter 2020 Financial Results
August 12, 2020 16:05 ET
|
Onconova Therapeutics, Inc.
INSPIRE Phase 3 trial survival events reachedTopline data anticipated Q3-2020 Conference call and webcast scheduled today, August 12, at 4:30 p.m. ET NEWTOWN, Pa., Aug. 12, 2020 (GLOBE NEWSWIRE)...
Aprea Therapeutics Reports Second Quarter 2020 Financial Results and Provides Update on Business Operations
August 11, 2020 16:15 ET
|
Aprea Therapeutics
BOSTON, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Onconova Therapeutics to Provide Corporate Update and Second Quarter 2020 Earnings on August 12, 2020
August 07, 2020 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Therapeutics Announces Compliance with Nasdaq Bid Price Requirement
August 04, 2020 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Therapeutics Announces that the Required Number of Survival Events Has Been Reached for the Pivotal Phase 3 INSPIRE Trial Data Analysis
July 29, 2020 13:30 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., July 29, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Therapeutics Announces Publication of Preclinical Data Supporting Rigosertib’s Mechanism of Action as a Targeted Anticancer Therapy
July 23, 2020 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., July 23, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Therapeutics Announces Publication of Phase 1 Results in Leukemia Research Exploring Oral Rigosertib in Combination with Azacitidine in Higher-Risk MDS
July 07, 2020 08:00 ET
|
Onconova Therapeutics, Inc.
RAS-focused mechanism of action and manageable side effect profile indicate potential promise for oral rigosertib as part of future combination therapies NEWTOWN, Pa., July 07, 2020 (GLOBE...
Onconova Therapeutics Announces Participation in Noble Capital Markets Investor Webinar
June 23, 2020 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., June 23, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Therapeutics Announces Presentation at the 25th Congress of the European Hematology Association (EHA)
June 12, 2020 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., June 12, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat...